跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT07752264
NCT07752264尚未招募1 期

An Open-label, Single-arm Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Equecabtagene Autoleucel Injection (Eque-cel) in Subjects With Immune-mediated Necrotizing Myopathy

Nanjing IASO Biotechnology Co., Ltd.4 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2026年8月15日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
尚未招募
入组人数
27
试验地点
4
主要终点
Phase I: Safety endpoint - Adverse Events (AEs)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is an open-label, single-arm Phase I/II clinical study to evaluate the efficacy and safety of Eque-cel Injection in patients with refractory immune-mediated necrotizing myopathy.

详细描述

This study is an open-label, single-arm Phase I/II clinical trial evaluating the safety and efficacy of Eque-cel in subjects with immune-mediated necrotizing myopathy (IMNM). The study consists of two phases: Phase I and Phase II. The Phase I component will evaluate the safety, tolerability and preliminary efficacy of Eque-cel to identify the recommended Phase 2 dose (RP2D). Following RP2D determination from Phase I, the Phase II stage will enroll additional subjects at this dose level to confirm the efficacy of Eque-cel injection in patients with IMNM. All subjects will undergo a primary follow-up period of 2 years after infusion of Eque-cel injection, followed by long-term follow-up extending up to 15 years.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •1. At the time of signing the informed consent form, the age is ≥ 18 years old.
  • •2.Based on the 2016 ENMC classification criteria, the clinical diagnosis is IMNM.
  • •3.At the time of screening, the anti-SRP antibody or anti-HMGCR antibody is positive.
  • •4. Refractory IMNM that failed or relapsed after standard treatment, and the disease is still active at the time of screening.
  • •5.The subjects must have appropriate organ functions.
  • •6.The subjects and their spouses agree to take effective contraceptive measures (excluding safe period contraception) from the time of the subject signing the informed consent form until one year after the CAR-T cell infusion.
  • •7. The subjects must agree to sign or personally write and present the informed consent form approved by the ethics committee before starting any screening procedures.

排除标准

  • •1. Having end-stage myositis with involvement of terminal organs may pose additional risks or interfere with the study assessment.
  • •2.Presence of irreversible muscle involvement and/or severe atrophy may bring additional risks or interfere with the study assessment.
  • •3.Uncontrolled interstitial lung disease or any other uncontrolled manifestations of IIM, as judged by the investigator, may require the use of prohibited drugs during the study period.
  • •4. Diagnosed with other inflammatory or non-inflammatory myopathies.
  • •5.Any other known autoimmune disease that the investigator considers to interfere with the accurate assessment of clinical symptoms of IMNM or place the patient at excessive risk.
  • •6. Those with a history of solid organ transplantation.
  • •7. History of autologous or allogeneic stem cell transplantation.
  • •8. Previous history of BCMA-targeted drug treatment.
  • •9.Having occurred or planned to undergo major surgery or surgical treatment within 4 weeks before enrollment or within 12 weeks after infusion.
  • •10. Known primary immunodeficiency (congenital or acquired).
  • •11. Having a clear history of mental disorder or a history of substance abuse for mental disorders that cannot be quit.
  • •12.The subject has uncontrollable active fungal， viral， bacterial or other infections (having persistent infection-related signs/symptoms， without improvement after appropriate anti-infection treatment) or infections requiring intravenous anti-infection drug treatment.
  • •13.Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and abnormal peripheral blood hepatitis B virus (HBV) DNA test (defined as HBV DNA quantification ≥ 100IU/ml or ≥ 1000 copies /ml or above the normal reference range of the testing center or positive for qualitative HBV DNA detection) ; hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive (defined as ≥ 1000 IU/mL); human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA positive (defined as ≥ 1000 IU/mL); Treponema pallidum specific antibody positive and positive for the rapid plasma reagin test for syphilis.
  • •14.Severe heart disease: including but not limited to unstable angina pectoris and/or myocardial infarction within 12 months of the screening period, any congestive heart failure (NYHA classification ≥ III), and a history of severe arrhythmia.
  • •15.Severe asthma or chronic obstructive pulmonary disease (COPD). Note: Mild or moderate asthma or COPD patients with stable conditions, after assessment and approval by the investigator and the sponsor, can be enrolled.
  • •16.Acute cerebrovascular disease events occurred within 6 months before enrollment, including transient ischemic attack or stroke history.
  • •17.Any serious and/or uncontrolled comorbid diseases as determined by the investigator to potentially interfere with the study assessment.
  • •18.Malignant tumors within 5 years before screening, excluding cured cervical carcinoma in situ, basal cell or squamous epithelial cell skin cancer, locally advanced prostate cancer after radical surgery, breast duct carcinoma in situ after radical surgery, or thyroid papillary carcinoma after radical surgery.
  • •19. Known history of allergy to cyclophosphamide, fludarabine, components of Eque-cel injection or supportive drugs required for toxicity management of CAR-T cell therapy (such as tocilizumab).
  • •21.Pregnant or lactating women.
  • •21. Other situations as determined by the investigator to be unsuitable for enrollment.

研究组 & 干预措施

Equecabtagene Autoleucel Injection（Eque-cel）

Experimental

Eligible subjects will receive single intravenous infusion of Eque-cel Injection after successful screening and baseline assessment. Eque-cel Injection will be infused at 1.0 x 10^6 CAR-T cells/kg or 0.5 x 10^6 CAR-T cells/kg。

干预措施: Equecabtagene Autoleucel Injection (Eque-cel) (Drug)

结局指标

主要结局

Phase I: Safety endpoint - Adverse Events (AEs)

时间窗: up to 2 years from Eque-cel Injection infusion

Incidence and severity of adverse events as assessed by NCI-CTCAE v5.0 (except CRS and ICANS assessed according to the criteria of 2019 ASTCT criteria).

Phase I: Safety endpoint-incidence of Dose-limiting toxicity (DLT)

时间窗: Time Frame: up to 28 days from Eque-cel Injection infusion

Percentage of participants who experienced DLT within 28 days after Eque-cel administration.

Phase II: Efficacy endpoint- TIS response

时间窗: up to the 2 years after Eque-cel Injection infusion

Proportion of participants achieving TIS response

次要结局

  • Phase I: Efficacy endpoint -TIS response(up to the 2 years after Eque-cel Injection Infusion)
  • Phase II:Efficacy endpoint -Proportion of participants achieving minimal improvement response (TIS ≥ 20 points)(From baseline to 12 months after Eque-cel Injection Infusion)
  • Phase I/II:Efficacy endpoint -Change in mean Total Improvement Score (TIS) value(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II:Efficacy endpoint -The changes in PtGA scores(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II:Efficacy endpoint -The changes in PhGA scores(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II:Efficacy endpoint-MMT-8(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II:Efficacy endpoint -HAO Scale(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II:Efficacy endpoint -CK(up to 2 years from Eque-cel Injection infusion)
  • The changes in MDAAT scores(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II:Efficacy endpoint -hormone dosage reduction(From baseline to 6 and 12 months after Eque-cel Injection Infusion)
  • Phase II:Safety endpoint - Adverse Events (AEs)(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II Pharmacokinetic Endpoint - Cmax (CAR-T cells)(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II Pharmacokinetic Endpoint - Tmax (CAR-T cells)(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II Pharmacokinetic Endpoint - AUC (CAR-T cells)(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II Pharmacokinetic Endpoint - Cmax (VCN)(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II Pharmacokinetic Endpoint - Tmax (VCN)(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II Pharmacokinetic Endpoint - AUC (VCN)(up to 2 years from Eque-cel Injection infusion)
  • hase I/II Pharmacodynamic Endpoint - inflammatory markers(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II Pharmacodynamic Endpoint - Serum immunoglobulin(up to 2 years from Eque-cel Injection infusion)
  • Phase I/II Pharmacodynamic Endpoint-sBCMA(up to 2 years from Eque-cel Injection infusion)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

招募中
不适用
An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant TherapyTriple-Negative Breast Cancer
NCT07525869Yonsei University40
已完成
2 期
A Phase IIa Study in Primary IgA Nephropathy Patients
NCT07634744S-INFINITY Pharmaceuticals Co., Ltd25
招募中
1 期
Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
NCT07448116Betta Pharmaceuticals Co., Ltd.164
招募中
2 期
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of TreatmentChronic Obstructive Pulmonary Disease (COPD)
NCT07684820Expedition Therapeutics, Inc600
招募中
3 期
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
NCT07321093Biocad292